I was investigating possible acquisitions or in-licensing...

I was investigating possible acquisitions or in-licensing opportunities for Biota. At my own direction and pro-bono of course.

Biota mentioned they was looking at Phase 2 ready candidates in areas of Biota's expertise and interest.

Biotron Limited (BIT) has a mid stage candidate for both HIV and HCV. Market cap of $20M. Pretty interesting work. And long patent protection. Many moons ago Biota dabbled with HIV and more recently dabbled with HCV.

Should we tell Russel?


NB - I did suggest we merge with Biocryst prior to our double backflip forward flip reverse somersault merger with the Nicovax mob. So, I do have street cred.